Oncothyreon terminates its $50 million at-the-market sales agreement

Board determines it was in best interest of the company to cancel deal

By Devika Patel

Knoxville, Tenn., Sept. 18 – Oncothyreon Inc. terminated a $50 million at-the-market sales agreement with Cowen and Co., LLC on Sept. 17, according to an 8-K filed Thursday with the Securities and Exchange Commission. The deal priced on Feb. 3, 2012.

The company said its board of directors decided it was in the best interests of the company and its stockholders to cancel the arrangement.

Oncothyreon is a Seattle biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.